Skip to main content
    L

    Ligand Pharmaceuticals Incorporated (LGND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $301.71
    -7.08 (-2.29%)

    Market Cap: $6.18B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ligand Pharmaceuticals Incorporated (LGND) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Ligand Pharmaceuticals (LGND) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Ligand Pharmaceuticals reported EPS of -$1.43, below the $1.42 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +35.89%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.97
    Range$2.38 - $3.17
    14 analysts
    Revenue Consensus
    $99.62M
    Range$87.81M - $109.32M
    13 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.36
    Range$2.31 - $2.41
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$2.30+2.6%
    60d ago$2.30+2.6%
    30d ago$2.30+2.5%
    7d ago$2.31+2.3%
    Current$2.36
    Revenue Consensus
    $76.14M
    Range$76.14M - $76.14M
    1 analysts

    Next Report

    LGND has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 40.1% above the $2.12 reported for the quarter ended Dec 31, 2025.

    LGND Earnings Call

    The latest LGND earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, LGND beat 35 and missed 5. Revenue for the quarter ended Sep 30, 2026 was $78.75M, down 31.8% from $115.46M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.43$1.42N/A-200.70%Miss-146.3%100 up, 1 downOct 29, 2026$78.75M
    Jun 30, 2026$2.22$1.34N/A+65.67%Beat+825.0%90 up, 2 downAug 6, 2026$63.69M
    Mar 31, 2026$1.63$1.80$1.66 - $1.96-9.44%Miss+22.6%60 up, 4 downMay 14, 2026$51.72M
    Dec 31, 2025$2.12$0.63N/A+236.51%Beat+66.9%73 up, 1 downFeb 26, 2026$59.67M
    Sep 30, 2025$3.09$1.93$1.60 - $2.09+60.10%Beat+67.9%62 up, 1 downNov 6, 2025$115.46M
    Jun 30, 2025$0.24$0.21N/A+14.29%Beat-82.9%70 up, 5 downAug 7, 2025$47.63M
    Mar 31, 2025$1.33$1.21$1.14 - $1.27+9.92%Beat+10.8%40 up, 2 downMay 8, 2025$45.33M
    Dec 31, 2024$1.27$1.19$1.05 - $1.35+6.71%Beat-8.0%71 up, 1 downFeb 27, 2025$42.81M
    Sep 30, 2024$1.84$1.35$1.17 - $1.68+36.30%Beat+80.4%71 up, 0 downNov 7, 2024$51.81M
    Jun 30, 2024$1.40$1.06$0.94 - $1.36+32.08%Beat-1.4%50 up, 0 downAug 6, 2024$41.53M
    Mar 31, 2024$1.20$0.83$0.56 - $0.93+44.58%Beat-47.4%50 up, 0 downMay 7, 2024$30.98M
    Dec 31, 2023$1.38$0.66$0.63 - $0.68+109.09%Beat+1.5%40 up, 0 downFeb 27, 2024$28.10M
    Sep 30, 2023$1.02$0.62$0.46 - $0.70+64.52%Beat-22.1%40 up, 0 downNov 8, 2023$32.87M
    Jun 30, 2023$1.42$0.66$0.61 - $0.68+115.15%Beat+37.9%41 up, 0 downAug 8, 2023$26.37M
    Mar 31, 2023$2.28$0.89$0.52 - $1.13+156.18%Beat+200.0%51 up, 0 downMay 4, 2023$43.98M
    Dec 31, 2022$1.36$1.19$1.04 - $1.30+14.29%Beat-24.4%41 up, 0 downFeb 22, 2023$50.38M
    Sep 30, 2022$1.31$0.43$0.38 - $0.46+204.65%Beat-17.1%50 up, 0 downNov 7, 2022$59.22M
    Jun 30, 2022$1.03$0.43$0.06 - $0.70+139.53%Beat-36.8%50 up, 0 downAug 8, 2022$50.13M
    Mar 31, 2022$0.76$0.66$0.44 - $0.89+15.15%Beat-46.1%60 up, 0 downMay 4, 2022$36.52M
    Dec 31, 2021$1.80$1.37$1.33 - $1.43+31.39%Beat+11.1%6N/AFeb 17, 2022$36.88M
    Sep 30, 2021$1.58$1.04$0.88 - $1.31+51.92%Beat+51.9%60 up, 0 downNov 9, 2021$64.83M
    Jun 30, 2021$1.63$1.36$1.10 - $1.53+19.85%Beat+63.0%6N/AJul 29, 2021$84.67M
    Mar 31, 2021$1.41$1.13$1.05 - $1.19+24.78%Beat+58.4%6N/AMay 3, 2021$55.15M
    Dec 31, 2020$1.62$1.09N/A+48.62%Beat+128.2%6N/AFeb 3, 2021$47.13M
    Sep 30, 2020$1.04$0.98$0.84 - $1.07+6.12%Beat+112.2%6N/AOct 30, 2020$41.85M
    Jun 30, 2020$1.00$0.76$0.65 - $0.97+31.58%Beat+47.1%6N/AAug 3, 2020$41.42M
    Mar 31, 2020$0.89$0.66$0.59 - $0.82+34.85%Beat-23.3%6N/AMay 6, 2020$33.16M
    Dec 31, 2019$0.71$0.65$0.58 - $0.68+9.23%Beat-58.2%4N/AFeb 6, 2020$27.00M
    Sep 30, 2019$0.49$0.62$0.54 - $0.65-20.97%Miss-62.9%4N/ANov 5, 2019$24.81M
    Jun 30, 2019$0.68$0.55$0.38 - $0.65+23.64%Beat-73.7%4N/AJul 30, 2019$24.99M
    Mar 31, 2019$1.16$15.45N/A-92.49%Miss-25.2%2N/AMay 2, 2019$43.48M
    Dec 31, 2018$1.70$1.22$1.15 - $1.24+39.34%Beat+29.8%5N/AFeb 7, 2019N/A
    Sep 30, 2018$1.32$1.03$0.98 - $1.08+28.16%Beat+91.3%5N/ANov 8, 2018$45.66M
    Jun 30, 2018$2.59$2.38N/A+8.82%Beat+286.6%2N/AAug 6, 2018$90.04M
    Mar 31, 2018$1.55$1.26$0.53 - $1.35+23.02%Beat+171.9%5N/AMay 8, 2018$56.16M
    Dec 31, 2017$1.31$1.19$1.06 - $1.20+10.08%Beat+4.8%5N/AFeb 21, 2018$50.47M
    Sep 30, 2017$0.69$0.61$0.51 - $0.75+13.11%Beat+11.3%5N/ANov 9, 2017$33.38M
    Jun 30, 2017$0.67$0.46$0.40 - $0.58+45.65%Beat+34.0%5N/AAug 7, 2017$28.00M
    Mar 31, 2017$0.57$0.72N/A-20.83%Miss-41.2%N/AN/AMay 9, 2017$29.27M
    Dec 31, 2016$1.25$1.19N/A+5.04%Beat+89.4%N/AN/AFeb 23, 2017$38.19M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $6.78, up 18.7% from the year before. It was $3.34 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$6.78+18.7%
    Dec 31, 2024$5.71-6.4%
    Dec 31, 2023$6.10+36.8%
    Dec 31, 2022$4.46-30.5%
    Dec 31, 2021$6.42+41.1%
    Dec 31, 2020$4.55+49.7%
    Dec 31, 2019$3.04-57.5%
    Dec 31, 2018$7.16+121.0%
    Dec 31, 2017$3.24-3.0%
    Dec 31, 2016$3.34N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,100 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,11014
    2026Q2Jun 30, 20267,46112
    2026Q1Mar 31, 20265,69413
    2025Q4Dec 31, 20256,38812
    2025Q3Sep 30, 20256,6299
    2025Q2Jun 30, 20255,62911
    2025Q1Mar 31, 20256,19411
    2024Q4Dec 31, 20246,92813

    2026Q3 Earnings Call

    Opening remarks

    Melanie Herman Head of Investor Relations Good morning, everyone, and welcome to Ligand's Third Quarter 2026 Earnings Call. With me on the call today are CEO, Todd Davis; Chief Financial Officer, Tavo Espinoza; Vice President of Portfolio Strategy and Investments, Lauren Hay; and Paul Hadden, Senior Vice President of Investments and Business Development. During the call today, we will review the financial results released earlier today and provide commentary on our recent business development activity and partner portfolio, followed by a question-and-answer session. Before we get started, I would like to point out that we will be discussing non-GAAP results, which exclude certain items such as stock-based compensation, amortization of intangible assets, amortization or impairment of financial royalty assets, transaction costs, and gains or losses from derivative assets and mark-to-market changes in investments, amongst others. I encourage you to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP measures, which can be found in today's release available on our website. Reconciliations of forward-looking non-GAAP measures are not provided because of the unreasonable effort associated with providing such reconciliations due to the variability in the occurrence of the amounts of certain components thereof. We believe these adjusted measures provide valuable insight into our core operating performance, both historically and moving forward. Our earnings release and a link to today's webcast can be found in the Investor Relations section of our website at ligand.com. This call is being recorded, and the audio portion will be archived in the Investors section of our website. On today's call, we will make forward-looking statements regarding our financial results and other matters related to the company's business. Please refer to the safe harbor statement related to these forward-looking statements, which are subject to risks and uncertainties. We remind you that actual events or results may differ materially from those projected or discussed and that all forward-looking statements are based upon currently available information. Ligand assumes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Ligand files with the Securities and Exchange Commission, or SEC, that can be found on Ligand's website at ligand.com or on the SEC's website at sec.gov. And with that, I'd like to turn the call over to our CEO, Todd Davis.

    Todd Davis CEO Thank you, Melanie, and good morning, everyone. We appreciate you joining us today. The third quarter was an important one for Ligand, with royalty revenue growing 51% year-over-year to approximately $70 million. Filspari, Ohtuvayre, and the addition of the XOMA commercial assets Vabysmo, Ojemda, and Miplyffa led that growth, with the Filspari launch in FSGS being a primary growth driver as well.

    Frequently Asked Questions About LGND

    When is Ligand Pharmaceuticals's next earnings date?

    Ligand Pharmaceuticals's next earnings report is expected for Feb 24, 2027.

    Did LGND beat earnings estimates last quarter?

    No. Ligand Pharmaceuticals reported EPS of -$1.43 for the quarter ended Sep 30, 2026, below the $1.42 estimate by 200.70%.

    What EPS do analysts expect from LGND next quarter?

    The consensus EPS estimate for Ligand Pharmaceuticals for the quarter ending Dec 31, 2026 is $2.97 from 14 analysts, with estimates from $2.38 to $3.17.

    How often does LGND beat earnings estimates?

    Ligand Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +22.88%.